Filing summary
Entity mismatch: The supplied filing is Flora Growth Corp.’s Form 10-K, not a filing for Zerostack Corp. It reports the fiscal year ended December 31, 2023; it is not a standalone fourth-quarter report. Financial amounts below are in U.S. dollars unless noted.
Business context and reporting period
Flora is a multinational cannabis and pharmaceutical company organized around consumer brands, including JustCBD and Vessel, and pharmaceutical and medical-cannabis distribution, primarily through Phatebo in Germany. In 2023 it sold its Colombian operations to focus on U.S. lifestyle brands and international pharmaceutical distribution. The audited statements are prepared under U.S. GAAP.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | $76.1 million | $33.4 million |
| Gross profit / gross margin | $17.7 million / 23% | $13.3 million / 40% |
| Operating loss | $50.4 million | $47.2 million |
| Net loss | $56.3 million | $52.6 million |
| Net loss from continuing operations | $46.7 million | $46.7 million |
| Cash used in operating activities | $8.4 million | $15.9 million |
- FGH contributed $38.3 million of 2023 revenue, compared with $0.1 million in 2022, following its December 2022 acquisition. JustCBD revenue was $31.1 million versus $26.4 million; Vessel revenue was $6.7 million versus $7.0 million.
- Gross margin contracted mainly because FGH distributes lower-margin pharmaceuticals. Total operating expenses were $68.1 million, including $39.5 million of goodwill and other asset impairments, versus $60.5 million in 2022.
- At year-end, cash and cash equivalents were $4.4 million, working capital was $5.1 million, total assets were $23.6 million, total liabilities were $17.2 million, and shareholders’ equity was $6.4 million. Cash declined from $8.9 million a year earlier.
- FGH had €1.8 million ($1.9 million) drawn on German credit facilities, bearing interest of 5.45%–6.46%; the filing says the outstanding balance is due within 12 months. The facilities total €4.0 million and have no set maturity date.
- Adjusted EBITDA, a non-GAAP measure, was a loss of $6.9 million, compared with a loss of $13.2 million in 2022. The company cautions that this measure may not be comparable across companies.
Material changes and unusual items
- Revenue more than doubled, principally reflecting a full year of JustCBD and the inclusion of FGH; the comparison is materially affected by acquisitions.
- Goodwill and other asset impairments totaled $39.5 million in 2023, including $23.4 million of goodwill impairment that eliminated the remaining goodwill associated with JustCBD and FGH. The company also recorded significant impairments of other long-lived assets.
- Colombian operations were classified as discontinued operations. The sale generated $0.6 million of stated purchase consideration; 2023 discontinued-operations loss was $9.7 million, including a $3.1 million loss on disposal.
- Florida issued stop-sale orders in October 2023 affecting 340 Just Brands hemp-extract products. The company estimated a $0.5 million revenue impact for 2023 and reported $1.6 million of affected inventory at year-end. Additional orders in early 2024 affected 231 products; the company estimated a $0.3 million revenue impact for Q1 2024.
- The company raised $2.7 million gross in a September 2023 unit offering, issuing shares and warrants. It also completed a 1-for-20 reverse stock split in June 2023.
Outlook, risks, and contingencies
- Going concern: Management and the independent auditor reported substantial doubt about Flora’s ability to continue as a going concern. Management said existing cash was insufficient to fund growth and meet obligations, and that additional financing, cost reductions, strategic arrangements, or asset sales may be needed. There is no assurance financing will be available on acceptable terms or at all. The auditor issued an unmodified opinion on the financial statements but included a going-concern emphasis.
- No quantified financial guidance: The filing provides no specific revenue, profit, or cash-flow forecast. Management describes plans to reduce costs, seek capital, and pursue growth, but says sustained profitability and positive operating cash flow are not assured. It noted that only Q3 2023 had produced net income and positive operating cash flow since inception.
- Regulatory and legal exposure: Flora is appealing a court ruling upholding Florida’s stop-sale orders. The Department alleges 215,154 violations for moving products outside Florida and seeks penalties of up to $5,000 per violation. Flora disputes the allegation and had not accrued a liability, citing uncertainty about the outcome. Other claims include litigation related to the FGH acquisition and claims seeking shares for alleged consulting services.
- Other risks: Cannabis laws remain unsettled, U.S. federal law prohibits marijuana, and CBD marketing is constrained by FDA rules. The filing also highlights product-liability and recall risks, inventory shelf life, supplier dependence, foreign-exchange exposure, potential dilution, and Nasdaq listing compliance.
- Nasdaq and governance: Flora regained compliance with Nasdaq’s minimum bid-price rule in June 2023, but was notified in December 2023 that it did not meet the audit-committee membership requirement after a director’s resignation. It received a cure period extending to the earlier of its next annual meeting or November 30, 2024, subject to the stated deadline if the meeting occurs before May 28, 2024.
- Management reported effective disclosure controls and internal control over financial reporting as of year-end. The company said a previously identified material weakness in goodwill impairment testing and purchase-price allocations had been remediated.
Important facts for investors to verify
- Flora Growth Corp. is the registrant in the supplied 10-K; confirm the intended company, since the request identifies Zerostack Corp.
- Review the going-concern disclosures, cash runway, subsequent financing, and ability to meet near-term obligations.
- Track the Florida stop-sale appeal and administrative penalty case, including affected inventory, sales restrictions, and any liability accruals.
- Assess whether revenue growth can translate into improved margins and cash generation, given acquisition-driven growth and 2023 impairments.
- Confirm the status of Nasdaq audit-committee compliance and any potential dilution from outstanding warrants, equity awards, or future financing.